“This is why the folks calling for his ousting a
Post# of 148250
Many, many, longs want NP removed because he’s inept and has ruined many, many fantastic opportunities for leronlimab to advance. He has progressed the molecule as far as he can and needs to step aside. The new CEO will make Nader’s unnecessary share awards worth half a billion and Nader will be thankful for that. The SP drops after CCs and after trailed trials (HIV BLA, CD10, CD12) because of NP or they drop after an r/s, so pick your poison. Both scenario is offer a buying opportunity for kings. I’ll take an r/s over another failed trial PR because at least we’ll have better leadership.
“Now, if the BLA isn't done by end of 2021 and we still haven't managed to generate a dollar from Covid, then it might be time to amputate.”
How many times are you going to allow NP to fail shareholders before realizing he needs to go? The HIV BLA will not be submitted in 2021.